News

Injectable Cefazolin Recalled Due to Possible Microbial Contamination


 

Hanford Pharmaceuticals Inc. is recalling four lots of cefazolin for injection due to the possibility of microbial contamination, which may pose a serious or life-threatening risk for some patients.

The recall affects 379,975 vials (1 g/10 mL) in lots distributed by Sandoz Inc. (C4650 and C4537) and Watson Pharmaceuticals Inc. (C4689 and C4665).

Certain lots of the active ingredient used to manufacture the product have been shown to contain microbial contamination, including Bacillus pumilus, Staphylococcus hominis, Propionibacterium acnes, and Micrococcus luteus.

Cefazolin injection is used to treat skin and skin structure, respiratory, and other infections. Users, hospitals, and clinics should stop using the affected lots immediately.

Patients who believe that they may have experienced an adverse reaction to the recalled product are advised to seek medical help.

For more information, contact the company by calling 315-476-7418. Adverse reactions experienced by users of this product should also be reported to the Food and Drug Administration's MedWatch Program at www.fda.gov/medwatch/report.htm

Recommended Reading

Daptomycin Deemed Approvable for S. aureus
MDedge Family Medicine
Diagnostics for Bioterrorism Agents on the Way
MDedge Family Medicine
Procalcitonin-Guided Protocol Can Cut Duration of Antibiotics for Pneumonia
MDedge Family Medicine
Low BMI Predicted Increased Mortality Risk in Septic Shock
MDedge Family Medicine
Rare Fungal Infection Emerges in Southwest
MDedge Family Medicine
Aerosolized Amphotericin B in The Works as a Fungal Prophylaxis
MDedge Family Medicine
High-Dose Aspergillosis Tx No Better Than Standard Dose
MDedge Family Medicine
Clinical Capsules
MDedge Family Medicine
Prophylaxis Still Essential After Rabies Exposure
MDedge Family Medicine
Antidepressants May Bolster Immune Function in HIV-Positive Patients
MDedge Family Medicine